Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation.
The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.
Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.08 Increased by +76.47% | -0.30 Increased by +73.62% |
| Mar 26, 25 | -0.95 Decreased by -226.07% | -0.33 Decreased by -189.44% |
| Nov 7, 24 | -0.32 Increased by +8.57% | -0.31 Decreased by -3.23% |
| Aug 19, 24 | -1.06 Decreased by -165.00% | -0.30 Decreased by -253.33% |
| Jun 20, 24 | -0.34 Increased by +54.67% | -0.37 Increased by +8.11% |
| Mar 28, 24 | -0.29 Increased by +57.97% | -0.39 Increased by +25.64% |
| Nov 9, 23 | -0.35 Increased by +52.05% | -0.46 Increased by +23.91% |
| Aug 10, 23 | -0.40 Increased by +38.46% | -0.46 Increased by +13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -6.50 M Increased by +36.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 192.00 K Increased by +N/A% | -44.62 M Decreased by -363.51% | Decreased by -23.24 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | 76.97 M Increased by +843.75% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 24 | 560.00 K Increased by +N/A% | -44.91 M Decreased by -368.81% | Decreased by -8.02 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -10.29 M Increased by +1.33% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -9.63 M Increased by +83.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.35 M Decreased by -0.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.58 M Decreased by -4.00% | Decreased by N/A% Decreased by N/A% |